|
J Biol Chem, Vol. 273, Issue 17, 10726-10732, April 24, 1998
Characterization of Insulin Receptor Substrate 4 in Human
Embryonic Kidney 293 Cells*
Valeria R.
Fantin,
Joshua D.
Sparling,
Jan W.
Slot ,
Susanna R.
Keller,
Gustav E.
Lienhard§, and
Brian E.
Lavan¶
From the Department of Biochemistry, Dartmouth Medical School,
Hanover, New Hampshire 03755 and Department of Cell
Biology, Medical School, Utrecht University,
3584 CX Utrecht, The Netherlands
 |
ABSTRACT |
We recently cloned IRS-4, a new member of the
insulin receptor substrate (IRS) family. In this study we have
characterized IRS-4 in human embryonic kidney 293 cells, where it was
originally discovered. IRS-4 was the predominant insulin-elicited
phosphotyrosine protein in these cells. Subcellular fractionation
revealed that about 50% of IRS-4 was located in cellular membranes,
and immunofluorescence indicated that IRS-4 was concentrated at the
plasma membrane. Immunoelectron microscopy conclusively established
that a large portion of the IRS-4 was located at the cytoplasmic
surface of the plasma membrane in both the unstimulated and
insulin-treated states. IRS-4 was found to be associated with two src
homology 2 (SH2) domain-containing proteins, phosphatidylinositol
3-kinase and Grb2, the adaptor to the guanine nucleotide exchange
factor for Ras. On the other hand, no significant association was
detected with two other SH2 domain proteins, the SH2-containing protein tyrosine phosphatase 2 and phospholipase C . Insulin-like growth factor I acting through its receptor was as effective as insulin in
eliciting tyrosine phosphorylation of IRS-4, but interleukin 4 and
epidermal growth factor were ineffective.
 |
INTRODUCTION |
Signal transduction from the insulin and
IGF-I1 receptors is initiated
by the activated receptors phosphorylating insulin receptor substrates
(IRSs) on multiple tyrosine residues. The IRSs in turn bind SH2
domain-containing signaling proteins. The binding of these SH2 domain
proteins activates them in various ways and thereby initiates signaling
cascades that regulate cell metabolism and proliferation (reviewed in
Refs. 1-3). Until recently, there appeared to be only two IRSs, IRS-1
and IRS-2. However, in the past year we have isolated and cloned two
more members of this family, IRS-3 and IRS-4 (4, 5). All four members
have a similar architecture, consisting of a NH2-terminal
pleckstrin homology domain followed by a phosphotyrosine binding domain
and COOH-terminal portion with tyrosine phosphorylation sites in short motifs that can bind to specific SH2 domains.
We discovered IRS-4 in human embryonic kidney 293 (HEK) cells as a
160-kDa protein that undergoes tyrosine phosphorylation in response to
insulin (5). Other than cloning, there has been no characterization of
IRS-4 and comparison of its properties with the other IRSs. The present
study describes its subcellular location, association with SH2 domain
proteins, and tyrosine phosphorylation in response to other growth
factors in HEK cells.
 |
EXPERIMENTAL PROCEDURES |
Antibodies--
Antibodies against Grb2 (SC255), SHP-2 (SC280),
and phospholipase C (SC426) were purchased from Santa Cruz
Biotechnology. Antiserum against the 85-kDa subunit of PI 3-kinase
(06-195) and antibodies against IRS-2 (06-506) were from Upstate
Biotechnology. An antiserum against the carboxyl-terminal peptide of
IRS-2, which was kindly provided by Dr. Jacalyn Pierce, National
Institutes of Health, was also used for some initial experiments. The
preparations of affinity-purified antibodies against Tyr(P) and the
carboxyl terminus of IRS-1 were those described previously (6). An
antiserum against a truncated form of human SHP-2 lacking the SH2
domains (7) was the generous gift of Dr. Zhizhuang Zhao, University of
Washington; it was used throughout for immunoblotting, whereas the
Santa Cruz antibody was used for immunoprecipitation.
Two types of rabbit antibodies were generated against IRS-4. One was
raised against the carboxyl-terminal 16 amino acids of human IRS-4,
coupled to hemocyanin via a cysteine at the amino terminus of the
synthetic peptide. The antibodies were affinity-purified on the
immobilized peptide as described by Lamphere and Lienhard (6). This
preparation is referred to as anti-IRS-4C. The other antibodies were
raised against a GST fusion protein with amino acids 994-1197 of mouse
IRS-4. This region of the mouse IRS-4 genomic DNA was amplified by PCR
using a 5' primer with an appended BamHI restriction site
and a 3' primer with a XbaI restriction site. The product
was ligated into the BamHI/XbaI sites of the pGEX-5X-3 plasmid (Amersham Pharmacia Biotech). The GST fusion protein
was expressed in Escherichia coli strain HB101 and then purified according to the method described by Amersham Pharmacia Biotech. The antibodies against the GST fusion protein were
affinity-purified from the serum by adsorption of the serum with
immobilized GST followed by chromatography on the immobilized GST
fusion protein, as described by Keller et al. (8). This
preparation is referred to as anti-IRS-4GST. Both types of antibodies
immunoprecipitated and immunoblotted IRS-4 from lysates of HEK cells.
Both types of antibodies are against regions of IRS-4 that show little
or no homology with IRS-1 or IRS-2 (5), and consequently there is no
reason to expect any cross-reactivity.
Cell Culture--
HEK cells were cultured as described
previously (9) and used upon reaching confluence. Before use cells were
put into serum-free Dulbecco's modified Eagle's medium for 2 h.
Unless stated otherwise, insulin treatment was with 1 µM
insulin for 10 min. All experiments with HEK cells, except for those in
Fig. 5, were performed with a line of HEK cells provided by Dr.
Zhizhuang Zhao at the University of Washington. Those in Fig. 5 were
performed with a line provided by Dr. Derek LeRoith at the National
Institutes of Health. This latter line showed slightly greater insulin
stimulation of IRS-4 tyrosine phosphorylation, and its content of
insulin and IGF-I receptors has previously been determined (10). In
this latter set of experiments, 60-mm plates of cells in medium with 1 mg/ml bovine serum albumin were treated for 10 min with various
concentrations of porcine insulin, human IGF-I (Boehringer Mannheim),
human IL-4 (R&D Systems), or human EGF (Upstate Biotechnology). The
medium was aspirated, and the cells were lysed in 1.5 ml of SDS sample buffer with 20 mM dithiothreitol, 1 mM sodium
vanadate, and a mixture of protease inhibitors (10 µM
leupeptin, 1 µM pepstatin, 10 µM EP475, 1 mM phenylmethanesulfonyl fluoride, 10 µg/ml aprotinin). The SDS samples were held at 100 °C for 4 min, and the DNA in them
sheared by passage through a syringe needle.
Cell Fractionation--
Plates (10-cm) of untreated or
insulin-treated HEK cells were washed with ice-cold 150 mM
NaCl, 10 mM sodium phosphate, pH 7.4, and scraped into 2 ml
of homogenization buffer (40 mM HEPES, 150 mM
NaCl, pH 7.4, with phosphatase inhibitors (10 mM sodium pyrophosphate, 10 mM NaF, 1 mM sodium vanadate)
and protease inhibitors (2 mM EDTA, 1 mM
phenylmethanesulfonyl fluoride, 10 µM leupeptin, 1 µM pepstatin, 10 µM EP475, and 10 µg/ml
aprotinin)). The cell suspension was lysed by passage 8 times through a
Balch homogenizer with a clearance of 0.011 inch (11). The homogenates
were diluted to 6 ml with homogenization buffer and centrifuged at
140,000 × g for 1 h to yield the cytosol and a
pellet of organelles. The latter was resuspended in 6 ml of
homogenization buffer containing 1% C12E9. The
resuspended material was centrifuged at 140,000 × g
for 1 h, to yield solubilized membranes and a pellet. The pellet
was dissolved in SDS sample buffer.
Immunoprecipitations--
Plates (10-cm) of untreated or
insulin-treated HEK cells were lysed in 6 ml of homogenization buffer
containing 1% C12E9. Insoluble material was
removed by centrifugation at 140,000 × g for 1 h.
Aliquots of the cleared lysates (0.8 ml containing about 1 mg of
protein) were immunoprecipitated with 10 µg of antibodies against
IRS-4, SHP-2, Grb2, or irrelevant IgG, or with 5 µl of antiserum
against PI 3-kinase at 4 °C for 2 h. The immune complexes were
then collected on 20 µl of protein A-Sepharose for 2 h. Tyr(P) proteins were isolated by incubation of 0.8 ml of the cleared lysate
with 20 µl of the monoclonal antibody against Tyr(P) 4G10 linked to
agarose (Upstate Biotechnology).
Immunoblotting--
Proteins were separated by
SDS-polyacrylamide gel electrophoresis and transferred to Immobilon-P
membranes (Millipore) for 2.5 h at 400 mA in 25 mM
Tris, 190 mM glycine, 20% methanol, 0.005% SDS. Tyr(P)
immunoblots were blocked with 3% bovine serum albumin in 150 mM NaCl, 20 mM Tris-HCl, pH 7.4 (TBS), and then
treated with anti-Tyr(P) at 4 µg/ml in TBS containing 0.2% albumin
followed by the secondary antibody in the same buffer. Immunoblots with the other antibodies were blocked in 5% nonfat dry milk in TBS, and
then treated with antibodies against IRS-4 at 4 µg/ml or against Grb2
or phospholipase C at 0.5 µg/ml, or antisera against PI 3-kinase
or SHP-2 at 1/1000 dilution in 1% milk in TBS and then with the
secondary antibody in the same buffer. Membranes were washed with 0.3%
Tween 20 in TBS. Blots were developed with goat anti-rabbit antibodies
conjugated to horseradish peroxidase (Bio-Rad), followed by
chemiluminescence detection (Pierce reagent).
Immunofluorescence--
Immunofluorescence was carried out with
subconfluent HEK cells grown on glass coverslips according to the
method described previously (12). In this method cells were fixed with
formaldehyde, permeabilized with saponin, and treated first with 5 µg/ml anti-IRS-4GST or, as a control, irrelevant rabbit
immunoglobulin, and then with goat antibodies against rabbit
immunoglobulin conjugated to fluorescein, as well as the DNA stain
4',6-diamidino-2-phenylindole. Anti-IRS-4GST, rather than anti-IRS-4C,
was used for both immunofluorescence and immunoelectron microscopy (see
below) because it was the more specific reagent. On an immunoblot of a
total HEK cell lysate anti-IRS-4GST gave only a single band at 160 kDa,
whereas anti-IRS-4C gave both this band and several bands of smaller
sizes.
Immunoelectron Microscopy--
Plates (10 cm) of basal and
insulin-treated HEK cells were fixed with 2% paraformaldehyde and
0.2% glutaraldehyde in 0.1 M sodium phosphate buffer, pH
7.4, for 1 h. The cells were washed with this buffer and scraped
into 1% paraformaldehyde in the same buffer. Ultrathin cryosectioning
and immunogold labeling were carried out as described previously (13).
Four different labeling experiments were performed with both untreated
and insulin-treated cells, and approximately 500 gold particles were
assigned to various organelles and counted with a section from each
labeling experiment. The percentages of gold particles in the various
locations from the four countings agreed with each other within ±3%
(S.E.). Labeling associated with the plasma membranes, intracellular
vesicles (mainly near the cell surface), and the cytoplasm was
observed. In addition, some labeling of the mitochondria and nuclei,
which amounted to 15 and 21% of the total, respectively, was found.
However, the latter was probably nonspecific, since labeling of human
HeLa cells with anti-IRS-4C gave about the same density of gold
particles over the mitochondria and nuclei even though HeLa cells had
no IRS-4 as assessed by immunoblotting. By contrast, the HeLa cells showed a lower density of labeling over the cytosol and virtually none
over the plasma membrane. Consequently, in calculating the percentages
of IRS-4 labeling of the plasma membranes, vesicles, and cytosol, we
have not included the gold particles over the mitochondria and
nuclei.
RNA Samples for Human Tissue Distribution--
A human RNA
master blot containing mRNA samples from 50 human tissues (7770-1)
and a human multiple tissue Northern blot (7760-1) were purchased from
CLONTECH.
 |
RESULTS |
Subcellular Distribution of IRS-4--
Untreated and
insulin-treated HEK cells were fractionated into cytosol and total
organelles, and the latter fraction was treated with the nonionic
detergent C12E9 to yield solubilized membranes and a pellet that probably consists largely of the cytoskeleton and
nuclei. These fractions were immunoblotted for IRS-4, Tyr(P), IRS-1,
IRS-2, and PI 3-kinase (Fig. 1).
Approximately 50% of the IRS-4 was in the membranes with the remainder
equally divided between the cytosol and the pellet. In contrast, both
IRS-1 and IRS-2 were primarily located in the cytosol. PI 3-kinase was
mainly in the cytosol and the membranes. Insulin treatment did not
significantly change the distribution of any of the proteins.

View larger version (46K):
[in this window]
[in a new window]
|
Fig. 1.
Subcellular distribution of IRS-4 in HEK
cells. Untreated ( ) and insulin-treated (+) HEK cells were
fractionated as described under "Experimental Procedures." The
total homogenate, cytosol (Cyt), membranes (Mem),
and residual pellet (Pel) were immunoblotted for IRS-4 with
anti-IRS-4C and for Tyr(P), IRS-1, IRS-2, and the 85-kDa subunit of
PI3K. The Tyr(P) blot shows the signal at the mobility of IRS-4 (160 kDa). The loads per lane were as shown, where load 1 was derived from
0.3% of a 10-cm plate, except for the IRS-2 blot where load 1 was
derived from 2.4% of a plate. The fractionation and analyses for IRS-4
and Tyr(P) were performed three times with similar results.
|
|
The predominant Tyr(P)-containing protein in the fractions had the same
mobility as IRS-4 (Fig. 1, Tyr(P) blot and data not shown). Several
types of experiments lead to the conclusion that this Tyr(P) protein is
almost entirely IRS-4. First, immunoprecipitation of approximately 75%
of the IRS-4 from C12E9 lysates of basal and
insulin-treated HEK cells depleted approximately the same proportion of
the Tyr(P) signal (see Fig. 4A, blots for IRS-4 and Tyr(P),
lanes 1-9). Second, immunoprecipitation of approximately 80% of the IRS-1 and IRS-2 from lysates of untreated and
insulin-treated HEK cells did not remove a detectable portion of this
Tyr(P) protein; moreover, the IRS-1 and IRS-2 isolated by
immunoprecipitation from the lysates showed no Tyr(P) upon
immunoblotting (Ref. 9 and data not shown). Thus, a significant portion
of this Tyr(P) protein is not one of these other two IRSs, which are of
approximately the same size. The finding that IRS-1 and IRS-2 were
primarily cytosolic, whereas the Tyr(P) protein was primarily in the
membranes and pellet (Fig. 1), is further evidence for this
conclusion.
IRS-4 in untreated cells exhibited significant Tyr(P) content, which
increased approximately 3-fold overall in response to insulin (Fig. 1,
Tyr(P) blot, total). This increase occurred mainly in the IRS-4 that
fractionated with the membranes and pellet; IRS-4 in the cytosol showed
little or no increase in Tyr(P) content.
Further information about the subcellular distribution of IRS-4 was
obtained by immunofluorescence and immunoelectron microscopy. Immunofluorescence showed distinct staining at the boundary of the
cell, weaker diffuse staining in the interior, and little or no
staining of the nucleus (Fig. 2). Thus, a
significant portion of the membrane-bound IRS-4 appeared to be at the
plasma membrane. Insulin treatment did not alter the distribution of
IRS-4. These results were confirmed by immunoelectron microscopy.
Considerable labeling at the inner surface of the plasma membrane was
observed (Fig. 3). The proportions of the
IRS-4 at the plasma membrane, on the surface of vesicles, and in the
cytosol of untreated and insulin-treated HEK cells were estimated by
counting gold particles and found to be 39, 16, and 45%, respectively,
for cells in both states (see "Experimental Procedures"). This
distribution agrees reasonably well with that found by subcellular
fractionation (Fig. 1).

View larger version (44K):
[in this window]
[in a new window]
|
Fig. 2.
Subcellular localization of IRS-4 in HEK
cells by immunofluorescence. Untreated and insulin-treated cells
were stained with anti-IRS-4GST or irrelevant rabbit IgG (left
side) and simultaneously for DNA (right side), as
described under "Experimental Procedures."
|
|

View larger version (115K):
[in this window]
[in a new window]
|
Fig. 3.
Subcellular localization of IRS-4 in HEK
cells by immunoelectron microscopy. Ultrathin cryosections of HEK
cells were labeled with anti-IRS-4GST followed by protein A 10-nm gold
particles. A, labeling at the plasma membranes between cells
(arrows indicate gold particles); B, labeling at
ruffled portions of the cell borders, which was often relatively high;
C, labeling associated with coated vesicles or pits at the
cell surface (arrows), which was not uncommon.
Bars: 200 nm.
|
|
Association of IRS-4 with SH2 Domain Proteins--
The amino acid
sequence of IRS-4 shows seven potential sites for tyrosine
phosphorylation in motifs that should bind to the two SH2 domains on
the 85-kDa regulatory subunit of PI 3-kinase, as well as one site in a
motif expected to bind the SH2 domain of Grb2 and another site in a
motif likely to bind to the NH2-terminal SH2 domain of the
tyrosine phosphatase SHP-2 and of phospholipase C (5). In order to
determine whether these associations occurred, we immunoprecipitated
IRS-4 from C12E9 lysates of untreated and insulin-treated HEK cells and then immunoblotted for PI 3-kinase, SHP-2, Grb2, and phospholipase C , as well as for IRS-4 and Tyr(P) (Fig. 4A). For comparison, the
Tyr(P) proteins were also immunoprecipitated and analyzed in the same
way. Immunoprecipitation with irrelevant rabbit IgG served as the
negative control (Fig. 4A). PI 3-kinase was associated with
IRS-4 in lysates from both untreated and insulin-treated cells (Fig.
4A, lanes 8 and 9); Grb2 was
associated with IRS-4 but only in lysates from insulin-treated cells.
There was no detectable association of SHP-2 or phospholipase C with
IRS-4. The Tyr(P) immunoprecipitates showed the same pattern of
associations as IRS-4 (Fig. 4A, lanes 12 and
13). This outcome is consistent with the observation that
IRS-4 is the predominant Tyr(P) protein in HEK cells (see Ref. 9 and
above). As expected, the immunoprecipitates with the irrelevant IgG
showed none of the proteins (lanes 16 and
17).

View larger version (57K):
[in this window]
[in a new window]
|
Fig. 4.
Association of IRS-4 with PI 3-kinase and
Grb2. Extracts of untreated ( ) and insulin-treated (+) HEK cells
in nonionic detergent were immunoprecipitated with antibodies against
IRS-4 (anti-IRS-4C), anti-Tyr(P) (4G10-agarose), and irrelevant rabbit
IgG (rIgGz) (A). The extract (Total),
depleted extracts (Unb for unbound), and immunoprecipitates
(IP) were blotted for IRS-4, Tyr(P), PI 3-kinase 85-kDa
subunit, SHP-2, Grb2, and phospholipase C . The Tyr(P) signal shown
is that from IRS-4. Extracts of untreated and insulin-treated HEK cells
were immunoprecipitated with antibodies against the 85-kDa subunit of
PI 3-kinase, Grb2, and SHP-2 (B). The extract, depleted
extracts, and immunoprecipitates were then blotted for IRS-4
(anti-IRS-4C), PI 3-kinase 85-kDa subunit, SHP-2, and Grb2. In
A and B the loads per lane were as shown, where
load 1 was derived from 1.5% of a 10-cm plate. A repetition of this
entire experiment gave similar results. Ins, insulin.
|
|
To confirm the associations found by immunoprecipitation of IRS-4, we
immunoprecipitated PI 3-kinase, Grb2, and SHP-2 and then immunoblotted
the immunoprecipitates for IRS-4, as well as PI 3-kinase, Grb2, and
SHP-2 (Fig. 4B). Under the conditions used, 75% or more of
the PI 3-kinase, Grb2, and SHP-2 was immunoprecipitated (Fig.
4B, compare Unb with Total). In
agreement with the results from the IRS-4 immunoprecipitation, IRS-4
was found associated with PI 3-kinase and Grb2, but there was little or
no association with SHP-2 (Fig. 4B, lanes 8 and
9, 12 and 13, and 16 and
17, respectively). Approximately the same amount of IRS-4
was associated with PI 3-kinase in the lysates of untreated and
insulin-treated cells (lanes 8 and 9), whereas
more IRS-4 was associated with Grb2 in the lysate from insulin-treated
cells than that from untreated cells (lanes 12 and
13). Finally, some Grb2 was present in the PI 3-kinase
immunoprecipitates (lanes 8 and 9), and some PI
3-kinase was present in the Grb2 immunoprecipitates (lanes
12 and 13); in both cases more was present in the
immunoprecipitates from the lysate of insulin-treated than untreated
cells. Most likely the co-precipitations of Grb2 and PI 3-kinase are
due to their simultaneous association with IRS-4 rather than to direct
binding of Grb2 to PI 3-kinase.
Tyrosine Phosphorylation of IRS-4 in Response to Growth
Factors--
A number of growth factors besides insulin, including
IGF-I and IL-4 but not EGF, elicit tyrosine phosphorylation of IRS-1 (3). We examined whether the same was true for IRS-4. In order to allow
a direct comparison of IGF-I and insulin, these experiments were
performed with a HEK line that was reported to contain about the same
number of IGF-I and insulin receptors per cell (approximately 10,000 of
each) (10). Fig. 5 indicates that IGF-I
and insulin stimulated tyrosine phosphorylation of IRS-4 by about
4-fold at maximal concentrations, and that the half-maximal effect of
each occurred at about 1 nM. Since there is no significant
binding of insulin to the IGF-I receptor or of IGF-I to the insulin
receptor at concentrations less than 10 nM (14), these
results suggest that the two receptors are approximately equally active
in tyrosine-phosphorylating IRS-4. The data in Fig. 5 also provide
another demonstration that IRS-4 is the predominant Tyr(P) protein
elicited by insulin and IGF-I in HEK cells.

View larger version (37K):
[in this window]
[in a new window]
|
Fig. 5.
Tyrosine phosphorylation of IRS-4 in HEK
cells in response to growth factors. Cells were treated with the
stated concentrations of insulin, IGF-I, IL-4, and EGF for 10 min and
then analyzed for Tyr(P) on IRS-4, as described under "Experimental
Procedures." The samples were also immunoblotted for IRS-4 with
anti-IRS-4C to verify equivalent loadings. The loads per lane were as
shown, where load 1 was derived from 0.5% of a 6-cm plate. A
repetition of this entire experiment yielded similar results.
|
|
Since Fig. 5 presents Tyr(P) immunoblots of whole cell lysates, it was
remotely possible that the 160-kDa protein, which is tyrosine
phosphorylated in response to IGF-I, was not IRS-4. However, we have
demonstrated by immunoprecipitation that the 160-kDa Tyr(P) elicited by
IGF-I as well as by insulin in this experiment was IRS-4. The SDS
lysates of the untreated cells and cells treated with 10 nM
IGF-I or insulin were made 0.3% in SDS and 1.5% in C12E9, and the IRS-4 was then
immunoprecipitated with anti-IRS-4C. For all the samples approximately
75% of the IRS-4 and the same proportion of the 160-kDa Tyr(P) protein
were immunoprecipitated, as assessed by immunoblotting the total
lysates, the lysates after immunoprecipitation, and the
immunoprecipitates with anti-IRS-4C and anti-Tyr(P) (data not
shown).
Fig. 5 also shows that neither IL-4 nor EGF at 10 nM
concentration for 10 min caused detectable tyrosine phosphorylation of IRS-4. Previous studies have shown that at this concentration and for
this time period IL-4 treatment of HEK cells activates the
transcription factor Stat6 (15), and EGF treatment activates the kinase
ERK-1 (16). These studies thus indicate that HEK cells contain
functional IL-4 and EGF receptors. However, it is uncertain whether the
amounts of these receptors would be sufficient to cause detectable
enhanced tyrosine phosphorylation of IRS-4. On the basis of Tyr(P)
blotting, there appeared to be more insulin and IGF-I receptors than
IL-4 and EGF receptors in the HEK cells. The tyrosine-phosphorylated
subunits of the activated insulin and IGF-I receptors, which
migrate at about 100 kDa, were very evident upon longer exposures of
the Tyr(P) blot in Fig. 5. However, neither the activated
tyrosine-phosphorylated forms of the JAK1 and JAK3 kinases, which are
elicited by and complexed with the activated IL-4 receptor and migrate
at about 130 kDa (17, 18), nor the activated tyrosine-phosphorylated
EGF receptor, which migrates at about 180 kDa (19), were evident (data
not shown).
Tissue Distribution of IRS-4--
As an approach to the human
tissue distribution of IRS-4, we attempted to determine the expression
of its mRNA. A significant amount of mRNA was not detected in
any tissue, and because of this outcome, only a brief description of
these experiments will be presented. First, a human mRNA Dot Blot
containing mRNA from 50 different human tissues including seven
major fetal tissues (100-500 ng/spot) was probed with single-stranded
digoxigenin-labeled cDNA corresponding to nucleotides 104-369 (5),
as described by Keller et al. (8). No significant signal was
given by any tissue, even though a positive control of 100 ng of HEK
mRNA gave a strong signal. The human Dot Blot was reprobed with a
32P-labeled riboprobe corresponding to nucleotides
1428-1896 (5), as described by Bell-Pederson et al. (20).
In this case, all the human tissues gave a very weak signal, whereas
the HEK mRNA gave an intense signal. Second, a Northern blot
containing mRNAs from eight major adult tissues (2 µg/lane) was
probed with the digoxigenin-labeled probe and then with the
32P-riboprobe. No mRNA was detected with the
digoxigenin-labeled probe. The riboprobe yielded some faint bands of
sizes less than that of the IRS-4 mRNA in HEK cells (see below)
after 4 days of exposure of the autoradiogram. In contrast, a Northern
blot of the same amount (2 µg) of HEK mRNA probed at the same
time with the same preparations of each probe yielded two strong bands, at 6 kilobases and greater than 9.5 kilobases (reported in Ref. 5).
 |
DISCUSSION |
Our results indicate that in HEK cells IRS-4 is the major
tyrosine-phosphorylated protein elicited by the activated insulin and
IGF-I receptors. Although the data does not demonstrate direct phosphorylation by the activated receptors, this is almost certainly the case. IRS-4 has a phosphotyrosine binding domain that is highly homologous to the one in IRS-1 that binds to these receptors and accounts in part for its direct phosphorylation (5, 21).
Despite the fact that HEK cells contain IRS-1 and IRS-2 as well as
IRS-4, the former showed no tyrosine phosphorylation in response to
insulin. We have previously estimated that HEK cells have about 25 times as much IRS-4 as IRS-1 (9); and from the relative intensities of
the IRS-4 and IRS-2 immunoblots (see Fig. 1), it seems likely that
there is also a large excess of IRS-4 over IRS-2. In addition, from the
nanogram amount of IRS-4 purified from an SDS lysate of HEK cells and
its yield from the lysate as assessed by immunoblotting for Tyr(P), we
have estimated that 1 mg of HEK cell protein contains about 0.3 µg of
IRS-4 (Ref. 9 and data not shown). Since a 10-cm plate of HEK cells
contains about 10 mg of protein and 5 × 106 cells, a
single HEK cell contains about 2 × 106 IRS-4
molecules, an amount that is 100-fold greater than approximately 2 × 104 insulin and IGF-I receptors. These considerations
thus suggest that no tyrosine phosphorylation of IRS-1 or IRS-2
occurred because the receptors were saturated with IRS-4. Studies in
which a cell expresses roughly equal numbers of two or more IRSs will
be needed to determine the relative efficiencies of the four IRSs as
substrates for the insulin and IGF-I receptors.
Immunoelectron microscopy revealed that approximately 40% of the IRS-4
was located at the cytoplasmic surface of the plasma membrane, both in
the unstimulated and insulin-treated state. The main basis for this
association is almost certainly not a direct interaction with the
insulin and IGF-I receptors, since as estimated above, there is not
enough of these receptors to account for more than a few percent of
IRS-4 bound at the plasma membrane. Moreover, if the association were
largely due to the binding of IRS-4 via its phosphotyrosine binding
domain to the receptors, then the amount at the plasma membrane should
have increased in response to insulin, since tyrosine phosphorylation of a motif in the receptors is required for binding to the
phosphotyrosine binding domain (22). More likely the basis for the
association is the binding of the pleckstrin homology domain of IRS-4
to one or more of the PI phosphates concentrated in the inner leaflet of the plasma membrane. Pleckstrin homology domains in various proteins
are known to bind to PI 4,5-bisphosphate, PI 3,4-bisphosphate, and PI
3,4,5-trisphosphate (23, 24). Alternatively, there may be a protein in
the plasma membrane that binds specifically to IRS-4 via the pleckstrin
homology domain or some other region of the latter. The observation
that the IRS-4 in the membrane and pellet fractions, but not that in
the cytosol fraction, became more highly tyrosine phosphorylated in
response to insulin suggests that the activated insulin receptor in the
plasma membrane preferentially phosphorylates the IRS-4 associated with
the membrane.
To our knowledge no earlier study has examined the subcellular
distribution of an IRS by immunoelectron microscopy, and thus direct
comparison of the distribution of IRS-4 with those of other IRSs is
not possible. The location of IRS-1 in 3T3-L1 adipocytes has previously
been examined by subcellular fractionation (25). In 3T3-L1 adipocytes,
IRS-1 is the predominant IRS present (26), so that the case is similar
to IRS-4 in HEK cells. Only 3% was present in the plasma membranes of
both untreated or insulin-treated adipocytes. Most (62%) was in the
low density microsomes, with the remainder in the cytosol (35%). Thus,
it may be that IRS-4 and IRS-1 are targeted to different locations in
the cell, although it should be recognized that the distribution of
IRS-1 upon subcellular fractionation may not necessarily coincide with
its distribution in vivo. Our finding from subcellular
fractionation that most of the IRS-1 is in the cytosol in HEK cells
contrasts with the distribution in 3T3-L1 adipocytes. One possible
explanation is that microsomal membranes of HEK cells lack the binding
sites for IRS-1 that are present in the adipocytes. Alternatively, it may be that microsomal binding sites are present in HEK cells but are
not available for IRS-1 because they are occupied by the more abundant
IRS-4 (see above).
The associations of IRS-4 with PI 3-kinase and Grb2 directly
demonstrates that like the other IRSs (1-3) IRS-4 is a docking and
effector protein for specific SH2 domain-containing proteins. As is the
case for IRS-1 (27), it is likely that the association of IRS-4 with PI
3-kinase results in the activation of this enzyme and the generation of
PI 3,4-bisphosphates and 3,4,5-trisphosphates. These lipids in turn
lead to activation of protein kinase B, and the latter in its activated
form regulates a number of cellular processes, including protection of
cells from apoptosis (28). Similarly, as in the case for IRS-1 (29), it
is likely that the association of IRS-4 with Grb2, which is a linker to
the guanine nucleotide exchange factor for Ras, leads to the elevation
of the GTP form of Ras, which in turn stimulates the downstream
mitogen-activated protein kinase cascade. In the case of both PI
3-kinase and the Grb2 complex, the localization of IRS-4 at the
cytoplasmic surface of the plasma membrane will facilitate signaling,
since PI 4,5-bisphosphate and the GDP form of Ras, the respective
substrates, are located in the same place. In agreement with these
expected roles for IRS-4 in signal transduction, treatment of HEK cells
with IGF-I has been found to activate both protein kinase B and the
mitogen-activated protein kinase ERK2 (30, 31). No association of IRS-4
was detected with SHP-2 or phospholipase C , even though there is a
tyrosine-phosphorylation motif in IRS-4 to which these would be
expected to bind. It is possible that this site is not phosphorylated, but it could also be that the interaction occurs in the cell but not
significantly in the lysate due to the large dilution of the proteins
in the lysate.
Approximately the same amount of PI 3-kinase was found associated with
IRS-4 from untreated and insulin-treated HEK cells, whereas the amount
of associated Grb2 was increased by insulin treatment. The most likely
explanation lies in the finding that IRS-4 from unstimulated cells
contained some Tyr(P). If this Tyr(P) is mainly located in the
YXXM motifs that bind to the SH2 domains of PI 3-kinase,
then association of IRS-4 with PI 3-kinase in untreated cells would
occur. Insulin treatment elevated the Tyr(P) content of IRS-4 about
4-fold. Presumably, it led to the phosphorylation of Tyr in the single
YVNM motif predicted to bind to the SH2 domain of Grb2. HEK cells are
transformed through integration of adenovirus genes (32). It is
possible that the transformation in some way causes the tyrosine
phosphorylation of IRS-4 in unstimulated cells, and that as a
consequence there is partial continuous activation of PI 3-kinase,
which may also contribute the transformed phenotype (28).
IRS-1 binds PI 3-kinase, Grb2, and SHP-2 (1-3). IRS-2 binds PI
3-kinase, and has been shown to bind to the isolated SH2 domain from
Grb 2 but not to that from SHP-2 (26). IRS-3 binds PI 3-kinase but has
not yet been examined for association with Grb2 or SHP-2 (4). Thus, the
signaling properties of IRS-4 overlap with those of the other IRSs, but
there are differences among the IRSs.
In various cell types IL-4, acting through the complex of its receptor
with the JAK tyrosine kinases, elicits tyrosine phosphorylation of
IRS-1 and IRS-2 (33, 34). On the other hand, abundant activated EGF
receptor does not cause tyrosine phosphorylation of IRS-1 in
adipocytes, whereas insulin does (19). Although no detectable tyrosine
phosphorylation of IRS-4 in response to IL-4 or EGF treatment of HEK
cells was observed, this outcome could simply be due to insufficient
amounts of the IL-4 or EGF receptors. Definitive determination of the
effect of IL-4 will require examination of the tyrosine phosphorylation
of IRS-4 in cell lines where IL-4 has been shown to cause tyrosine
phosphorylation of IRS-1 and IRS-2, whereas the effect of EGF should be
assessed in a cell line with equal amounts of insulin and EGF
receptors.
In our initial effort at determining the tissue distribution of IRS-4,
we have been unable to detect the mRNA in human tissues, even
though it is easily detected in HEK cells. This result suggests that
IRS-4 is not abundant and/or is expressed only in certain specific cell
types. By contrast, IRS-1 and IRS-2 have widespread tissue
distributions (26, 35), and IRS-3 is present in a number of tissues
(36). In the future it should be possible to determine the tissue
distribution of IRS-4 mRNA and protein in a species more amenable
to experimentation, such as mouse, by sensitive methods such as reverse
transcription PCR, immunoprecipitation followed by immunoblotting, and
immunofluorescence. We are currently generating mice with targeted
disruption of the IRS-4 gene. Comparison of these with normal mice
should allow unambiguous determination of the IRS-4 tissue
distribution, as well as provide information about the physiological
role of IRS-4.
 |
ACKNOWLEDGEMENTS |
We thank Ellen T. Chang for performing
preliminary experiments, Viola Oorschot for expert technical assistance
in the immunoelectron microscopy, Dr. Susan Crosthwaite for help with
the riboprobe, and Darsie Riccio for expert secretarial help.
 |
FOOTNOTES |
*
This work was supported by National Institutes of Health
Grant DK42816.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
To whom correspondence should be addressed. Tel.: 603-650-1627;
Fax: 603-650-1128; E-mail: gustav.e.lienhard{at}dartmouth.edu.
¶
Present address: Metabolex Inc., 3876 Bay Center Place,
Hayward, CA 94545, Tel.: 510-293-8800.
1
The abbreviations used are: IGF-I, insulin-like
growth factor I; C12E9, nonylethylene glycol
dodecyl ether; GST, glutathione S-transferase; HEK, human
embryonic kidney 293; IL-4, interleukin 4; IRS, insulin receptor
substrate; PI, phosphatidylinositol; SH2, Src homology 2; SHP-2,
SH2-containing protein tyrosine phosphatase 2; Tyr(P), phosphotyrosine;
PCR, polymerase chain reaction; EGF, epidermal growth factor.
 |
REFERENCES |
-
White, M. F.,
and Kahn, C. R.
(1994)
J. Biol. Chem.
269,
1-4[Free Full Text]
-
Keller, S. R.,
and Lienhard, G. E.
(1994)
Trends Cell Biol.
4,
115-119[CrossRef][Medline]
[Order article via Infotrieve]
-
Myers, M. G.,
and White, M. F.
(1996)
Annu. Rev. Pharmacol. Toxicol.
36,
615-658[CrossRef][Medline]
[Order article via Infotrieve]
-
Lavan, B. E.,
Lane, W. S.,
and Lienhard, G. E.
(1997)
J. Biol. Chem.
272,
11439-11443[Abstract/Free Full Text]
-
Lavan, B. E.,
Fantin, V. R.,
Chang, E. T.,
Lane, W. S.,
Keller, S. R.,
and Lienhard, G. E.
(1997)
J. Biol. Chem.
272,
21403-21407[Abstract/Free Full Text]
-
Lamphere, L.,
and Lienhard, G. E.
(1992)
Endocrinology
131,
2196-2202[Abstract/Free Full Text]
-
Zhao, Z.,
Larocque, R.,
Ho, W.-T.,
Fischer, E. H.,
and Shen, S.-H.
(1994)
J. Biol. Chem,.
269,
8780-8785[Abstract/Free Full Text]
-
Keller, S. R.,
Scott, H. M.,
Mastick, C. C.,
Aebersold, R.,
and Lienhard, G. E.
(1995)
J. Biol. Chem.
270,
23612-23618[Abstract/Free Full Text]
-
Kuhne, M. R.,
Zhao, Z.,
and Lienhard, G. E.
(1995)
Biochem. Biophys. Res. Commun.
211,
190-197[CrossRef][Medline]
[Order article via Infotrieve]
-
Beitner-Johnson, D.,
and LeRoith, D.
(1995)
J. Biol. Chem.
270,
5187-5190[Abstract/Free Full Text]
-
Balch, W. E.,
and Rothman, J. E.
(1985)
Arch. Biochem. Biophys.
240,
413-425[CrossRef][Medline]
[Order article via Infotrieve]
-
Ross, S. A.,
Scott, H. M.,
Morris, N. J.,
Leung, W.-Y.,
Mao, F.,
Lienhard, G. E.,
and Keller, S. R.
(1996)
J. Biol. Chem.
271,
3328-3332[Abstract/Free Full Text]
-
Heijnen, H. F. G.,
Oorschot, V.,
Sixma, J. J.,
Slot, J. W.,
and James, D. E.
(1997)
J. Cell Biol.
138,
323-330[Abstract/Free Full Text]
-
Kjeldsen, T.,
Andersen, A. S.,
Wiberg, F. C.,
Rasmussen, J. S.,
Schaffer, L.,
Balschmidt, P.,
Moller, K. B.,
and Moller, N. P. H.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
4404-4408[Abstract/Free Full Text]
-
Mikita, T.,
Campbell, D.,
Wu, P.,
Williamson, K.,
and Schindler, U.
(1996)
Mol. Cell. Biol.
16,
5811-5820[Abstract]
-
Bennett, A. M.,
Hausdorff, S. F.,
O'Reilly, A. M.,
Freeman, R. M.,
and Neel, B. G.
(1996)
Mol. Cell. Biol.
16,
1189-1202[Abstract]
-
Johnston, J. A.,
Kawamura, M.,
Kirken, R. A.,
Chen, Y. Q.,
Blake, T. B.,
Shibuya, K.,
Ortaldo, J. R.,
McVicar, D. W.,
and O'Shea, J. J.
(1994)
Nature
370,
151-153[CrossRef][Medline]
[Order article via Infotrieve]
-
Witthuhn, B. A.,
Silvennoinen, O.,
Miura, O.,
Lai, K. S.,
Cwik, C.,
Lie, E. T.,
and Ihle, J. N.
(1994)
Nature
370,
153-157[CrossRef][Medline]
[Order article via Infotrieve]
-
Hardy, R. W.,
Gupta, K. B.,
McDonald, J. M.,
Williford, J.,
and Wells, A.
(1996)
Endocrinology
136,
431-439[Abstract]
-
Bell-Pederson, D.,
Dunlap, J. C.,
and Loros, J. J.
(1996)
Mol. Cell. Biol.
16,
513-521[Abstract]
-
Yenush, L.,
Makati, K. J.,
Smith-Hall, J.,
Ishibashi, O.,
Myers, M. G.,
and White, M. F.
(1996)
J. Biol. Chem.
271,
24300-24306[Abstract/Free Full Text]
-
Wolf, G.,
Trub, T.,
Ottinger, E.,
Groninga, L.,
Lynch, A.,
White, M. F.,
Miyazaki, M.,
Lee, J.,
and Shoelson, S. E.
(1995)
J. Biol. Chem.
270,
27407-27410[Abstract/Free Full Text]
-
Lemmon, M. A.,
Falasca, M.,
Ferguson, K. M.,
and Schlessinger, J.
(1997)
Trends Cell Biol.
7,
237-242
-
Rameh, L. E.,
Arvidsson, A. K.,
Carraway, K. L.,
Couvillon, A. D.,
Rathbun, G.,
Crompton, A.,
VanRenterghem, B.,
Czech, M. P.,
Ravichandran, K. S.,
Burakoff, S. J.,
Wang, D. S.,
Chen, C. S.,
and Cantley, L. C.
(1997)
J. Biol. Chem.
272,
22059-22066[Abstract/Free Full Text]
-
Heller-Harrison, R. A.,
Morin, M.,
and Czech, M. P.
(1995)
J. Biol. Chem.
270,
24442-24450[Abstract/Free Full Text]
-
Sun, X. J.,
Pons, S.,
Wang, L.-M.,
Zhang, Y.,
Yenush, L.,
Burks, D.,
Myers, M. G.,
Glasheen, E.,
Copeland, N. G.,
Jenkins, N. A.,
Pierce, J. H.,
and White, M. F.
(1997)
Mol. Endocrinol.
11,
251-262[Abstract/Free Full Text]
-
Lamphere, L.,
Carpenter, C. L.,
Sheng, Z.-F.,
Kallen, R. G.,
and Lienhard, G. E.
(1994)
Am. J. Physiol.
266,
E486-E494[Abstract/Free Full Text]
-
Marte, B. M.,
and Downward, J.
(1997)
Trends Biochem. Sci.
22,
355-358[CrossRef][Medline]
[Order article via Infotrieve]
-
Myers, M. G.,
Wang, L.-M.,
Sun, X. J.,
Zhang, Y.,
Yenush, L.,
Schlessinger, J.,
Pierce, J. H.,
and White, M. F.
(1994)
Mol. Cell. Biol.
14,
3577-3587[Abstract/Free Full Text]
-
Alessi, D. R.,
Andjelkovic, M.,
Caudwell, B.,
Cron, P.,
Morrice, N.,
Cohen, P.,
and Hemmings, B. A.
(1996)
EMBO J.
15,
6541-6551[Medline]
[Order article via Infotrieve]
-
Suzuki, J.,
Kaziro, Y.,
and Koide, H.
(1997)
Oncogene
15,
1689-1697[CrossRef][Medline]
[Order article via Infotrieve]
-
Graham, F. L.,
Smiley, J.,
Russell, W. C.,
and Nairn, R.
(1977)
J. Gen. Virol.
36,
59-174[Abstract/Free Full Text]
-
Johnston, J. A.,
Wang, L.-M.,
Hanson, E. P.,
Sun, X.-J.,
White, M. F.,
Oakes, S. A.,
Pierce, J. H.,
and O'Shea, J. J.
(1995)
J. Biol. Chem.
270,
28527-28530[Abstract/Free Full Text]
-
Burfoot, M. S.,
Rogers, N. C.,
Watling, D.,
Smith, J. M.,
Pons, S.,
Paonessaw, G.,
Pellegrini, S.,
White, M. F.,
and Kerr, I. M.
(1997)
J. Biol. Chem.
272,
24183-24190[Abstract/Free Full Text]
-
Sun, X. J.,
Wang, L.-M.,
Zhang, Y.,
Yenush, L.,
Myers, M. G.,
Glasheen, E.,
Lane, W. S.,
Pierce, J. H.,
and White, M. F.
(1995)
Nature
137,
173-177
-
Sciacchitano, A.,
and Taylor, S. I.
(1997)
Endocrinology
138,
4931-4940[Abstract/Free Full Text]
Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
J. Wauman, A.-S. De Smet, D. Catteeuw, D. Belsham, and J. Tavernier
Insulin Receptor Substrate 4 Couples the Leptin Receptor to Multiple Signaling Pathways
Mol. Endocrinol.,
April 1, 2008;
22(4):
965 - 977.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. M. Hinsby, J. V. Olsen, and M. Mann
Tyrosine Phosphoproteomics of Fibroblast Growth Factor Signaling: A ROLE FOR INSULIN RECEPTOR SUBSTRATE-4
J. Biol. Chem.,
November 5, 2004;
279(45):
46438 - 46447.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. A. Mihindukulasuriya, G. Zhou, J. Qin, and T.-H. Tan
Protein Phosphatase 4 Interacts with and Down-regulates Insulin Receptor Substrate 4 following Tumor Necrosis Factor-{alpha} Stimulation
J. Biol. Chem.,
November 5, 2004;
279(45):
46588 - 46594.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Zhang, M. Karas, H. Zhao, S. Yakar, and D. LeRoith
14-3-3{sigma} Mediation of Cell Cycle Progression Is p53-independent in Response to Insulin-like Growth Factor-I Receptor Activation
J. Biol. Chem.,
August 13, 2004;
279(33):
34353 - 34360.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Dupont, M. Karas, and D. LeRoith
The Cyclin-dependent Kinase Inhibitor p21CIP/WAF Is a Positive Regulator of Insulin-like Growth Factor I-induced Cell Proliferation in MCF-7 Human Breast Cancer Cells
J. Biol. Chem.,
September 26, 2003;
278(39):
37256 - 37264.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Schreyer, D. Ledwig, I. Rakatzi, I. Kloting, and J. Eckel
Insulin Receptor Substrate-4 Is Expressed in Muscle Tissue without Acting as a Substrate for the Insulin Receptor
Endocrinology,
April 1, 2003;
144(4):
1211 - 1218.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Dupont, S. E. Dunn, J. C. Barrett, and D. LeRoith
Microarray Analysis and Identification of Novel Molecules Involved in Insulin-like Growth Factor-1 Receptor Signaling and Gene Expression
Recent Prog. Horm. Res.,
January 1, 2003;
58(1):
325 - 342.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Sano, S. C. H. Liu, W. S. Lane, J. E. Piletz, and G. E. Lienhard
Insulin Receptor Substrate 4 Associates with the Protein IRAS
J. Biol. Chem.,
May 24, 2002;
277(22):
19439 - 19447.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Kabuta, F. Hakuno, T. Asano, and S.-I. Takahashi
Insulin Receptor Substrate-3 Functions as Transcriptional Activator in the Nucleus
J. Biol. Chem.,
February 22, 2002;
277(9):
6846 - 6851.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Dupont, J. Khan, B.-H. Qu, P. Metzler, L. Helman, and D. LeRoith
Insulin and IGF-1 Induce Different Patterns of Gene Expression in Mouse Fibroblast NIH-3T3 Cells: Identification by cDNA Microarray Analysis
Endocrinology,
November 1, 2001;
142(11):
4969 - 4975.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. SESTI, M. FEDERICI, M. L. HRIBAL, D. LAURO, P. SBRACCIA, and R. LAURO
Defects of the insulin receptor substrate (IRS) system in human metabolic disorders
FASEB J,
October 1, 2001;
15(12):
2099 - 2111.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Tsuji, Y. Kaburagi, Y. Terauchi, S. Satoh, N. Kubota, H. Tamemoto, F. B. Kraemer, H. Sekihara, S. Aizawa, Y. Akanuma, et al.
Subcellular Localization of Insulin Receptor Substrate Family Proteins Associated With Phosphatidylinositol 3-Kinase Activity and Alterations in Lipolysis in Primary Mouse Adipocytes From IRS-1 Null Mice
Diabetes,
June 1, 2001;
50(6):
1455 - 1463.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
M. Karas, A. P. Koval, Y. Zick, and D. LeRoith
The Insulin-Like Growth Factor I Receptor-Induced Interaction of Insulin Receptor Substrate-4 and Crk-II
Endocrinology,
May 1, 2001;
142(5):
1835 - 1840.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
K. Tsuruzoe, R. Emkey, K. M. Kriauciunas, K. Ueki, and C. R. Kahn
Insulin Receptor Substrate 3 (IRS-3) and IRS-4 Impair IRS-1- and IRS-2-Mediated Signaling
Mol. Cell. Biol.,
January 1, 2001;
21(1):
26 - 38.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
M. L. Hribal, M. Federici, O. Porzio, D. Lauro, P. Borboni, D. Accili, R. Lauro, and G. Sesti
The Gly->Arg972 Amino Acid Polymorphism in Insulin Receptor Substrate-1 Affects Glucose Metabolism in Skeletal Muscle Cells
J. Clin. Endocrinol. Metab.,
May 1, 2000;
85(5):
2004 - 2013.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
C. A. Molloy, F. E. B. May, and B. R. Westley
Insulin Receptor Substrate-1 Expression Is Regulated by Estrogen in the MCF-7 Human Breast Cancer Cell Line
J. Biol. Chem.,
April 21, 2000;
275(17):
12565 - 12571.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. N. Winnay, J. C. Bruning, D. J. Burks, and C. R. Kahn
Gab-1-mediated IGF-1 Signaling in IRS-1-deficient 3T3 Fibroblasts
J. Biol. Chem.,
March 31, 2000;
275(14):
10545 - 10550.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Uchida, M. G. Myers Jr., and M. F. White
IRS-4 Mediates Protein Kinase B Signaling during Insulin Stimulation without Promoting Antiapoptosis
Mol. Cell. Biol.,
January 1, 2000;
20(1):
126 - 138.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
V. R. Fantin, Q. Wang, G. E. Lienhard, and S. R. Keller
Mice lacking insulin receptor substrate 4 exhibit mild defects in growth, reproduction, and glucose homeostasis
Am J Physiol Endocrinol Metab,
January 1, 2000;
278(1):
E127 - E133.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B.-H. Qu, M. Karas, A. Koval, and D. LeRoith
Insulin Receptor Substrate-4 Enhances Insulin-like Growth Factor-I-induced Cell Proliferation
J. Biol. Chem.,
October 29, 1999;
274(44):
31179 - 31184.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Marin-Hincapie and R. S. Garofalo
The Carboxyl Terminal Extension of the Drosophila Insulin Receptor Homologue Binds IRS-1 and Influences Cell Survival
J. Biol. Chem.,
August 27, 1999;
274(35):
24987 - 24994.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. V. Chaika, N. Chaika, D. J. Volle, H. Hayashi, Y. Ebina, L.-M. Wang, J. H. Pierce, and R. E. Lewis
Mutation of Tyrosine 960 within the Insulin Receptor Juxtamembrane Domain Impairs Glucose Transport but Does Not Inhibit Ligand-mediated Phosphorylation of Insulin Receptor Substrate-2 in 3T3-L1 Adipocytes
J. Biol. Chem.,
April 23, 1999;
274(17):
12075 - 12080.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Zhou, H. Chen, P. Xu, L.-N. Cong, S. Sciacchitano, Y. Li, D. Graham, A. R. Jacobs, S. I. Taylor, and M. J. Quon
Action of Insulin Receptor Substrate-3 (IRS-3) and IRS-4 to Stimulate Translocation of GLUT4 in Rat Adipose Cells
Mol. Endocrinol.,
March 1, 1999;
13(3):
505 - 514.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
V. R. Fantin, B. E. Lavan, Q. Wang, N. A. Jenkins, D. J. Gilbert, N. G. Copeland, S. R. Keller, and G. E. Lienhard
Cloning, Tissue Expression, and Chromosomal Location of the Mouse Insulin Receptor Substrate 4 Gene
Endocrinology,
March 1, 1999;
140(3):
1329 - 1337.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
R. M. K. Poltilove, A. R. Jacobs, C. R. Haft, P. Xu, and S. I. Taylor
Characterization of Drosophila Insulin Receptor Substrate
J. Biol. Chem.,
July 21, 2000;
275(30):
23346 - 23354.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Dupont, A. M. Fernandez, C. A. Glackin, L. Helman, and D. LeRoith
Insulin-like Growth Factor 1 (IGF-1)-induced Twist Expression Is Involved in the Anti-apoptotic Effects of the IGF-1 Receptor
J. Biol. Chem.,
July 6, 2001;
276(28):
26699 - 26707.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1998 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|